China’s phase 2 trial finds COVID-19 vaccine safe, inducing immune response
London: A phase 2 trial of a COVID-19 vaccine candidate conducted in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet.
The results provide data from a wider group of participants than the phase 1 trial, which was published in May. Phase 1 trial involved 108 healthy adults and it demonstrated promising results.
“The phase 2 trial adds further evidence on safety and immunogenicity in a large population than the phase 1 trial. This is an important step in evaluating this earlystage experimental vaccine and phase 3 trials are now underway,” said Professor Fengcai Zhu from Jiangsu Provincial Centre for Disease Control and Prevention, China.
According to The Lancet, the trial of the Ad5 vectored COVID-19 vaccine candidate was conducted in the central
Chinese city of Wuhan with 508 participants taking part. Approximately two thirds of participants were aged 18-44 years, with a quarter aged 45-54 years, and 13 percent aged 55 years or older.
Since elderly individuals face a high risk of serious illness and even death associated with COVID-19 infection, they are an important target population for a COVID-19 vaccine, said Professor Wei Chen from the Beijing
Institute of Biotechnology in Beijing, China.
“It is possible that an additional dose may be needed in order to induce a stronger immune response in the elderly population, but further research is underway to evaluate this,” Chen said.
To battle against COVID-19, scientists around the world are racing against time to accelerate the development of new treatments and vaccines.